Company intelligence / Profile preview

Spear Pharmaceuticals

Randolph, New Jersey, USAspearpharma.com ↗

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

Spear Pharmaceuticals has developed and commercialized multiple FDA-approved first-to-market generic/bioequivalent dermatological products. Clinical trials have demonstrated bioequivalence to branded reference drugs such as Retin-A Micro® and Carac®. Over a million prescriptions containing their formulations have been dispensed since launch. The company continues to develop additional specialty dermatology generics.[1][2][5]

Therapeutic areas: Dermatology
Modalities: small molecules (topical dermatological drugs such as tretinoin and fluorouracil)[1][3][6]
Industry: Biotech

Drug pipeline

3 assets

ezogabine

Commercial

Indications: Epilepsy

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Spear Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spear Pharmaceuticals.

Explore the full profile